The Danish biotech firm, Bavarian Nordic A/S has entered a deal with the Indian Serum Institute of India, SII for supplying its Mpox vaccines across Indian markets. The move is part of a development of increasing vaccine production in preparation to better prepare itself in light of the Mpox surges worldwide.

Key Takeaways
Technology Transfer & Manufacturing:

• Bavarian Nordic will license its technology to SII.

• The company, Serum Institute, will manufacture the Mpox vaccine for the Indian domestic market while offering contract manufacturing services to Bavarian Nordic to increase the global production capacity.

Global Mpox Situation:

• In total, over 65,700 cases have been reported globally in 2024, mainly in the Democratic Republic of Congo, and a total of 1,200 deaths.

• A mutated strain of the monkeypox virus has been detected in Africa, the US, the UK, and Thailand, spreading more rapidly and showing a higher mortality rate.

• Children have been the most susceptible to this outbreak.

Statements from Leaders:

• Adar Poonawalla, CEO of Serum Institute of India:

We are committed to using our manufacturing might and speed of response to better prepare for epidemics and to expand access to life-saving vaccines, protecting vulnerable populations and reducing the global burden of Mpox.

• Paul Chaplin, President and CEO of Bavarian Nordic:

Scoping global manufacturing is crucial so the vaccine becomes equitably available to all countries; hence, we are elated in this partnership with SII -the world's largest-volume vaccine manufacturer.

Financial Model:
It will form an advance-sale arrangement, milestone arrangement in terms of profitability, in particular.

Global Cooperation:
Bavarian Nordic is looking for opportunities for local manufacture with global partners to support vaccine supply globally.The strategic partnership between Bavarian Nordic and the Serum Institute of India shows that there is a growing need for global collaboration to address public health challenges. Equitable access to Mpox vaccines will be ensured as epidemic preparedness in India and elsewhere is strengthened.